Navigation Links
Luminex Corporation Vice President of Biodefense to Speak at DTRA'S 2011 CBD S&T Conference
Date:11/14/2011

AUSTIN, Texas, Nov. 14, 2011 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced Dr. Amy Altman, vice president of Biodefense will present at the Defense Threat Reduction Agency's (DTRA) 2011 Chemical and Biological Defense Science and Technology (CBD S&T) Conference, which takes place November 14-16, 2011 in Las Vegas, Nevada.

(Logo:  http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

During the conference, Dr. Altman will present "Fully automated xMAP®-based system for the multiplex detection of biothreat agents and emerging infectious diseases" in the Novel Next Generation System Platform Technologies session. Dr. Altman's presentation will take place on Tuesday, November 15, 2011 at 9:30 a.m. at the Mirage Las Vegas, Grand Ballroom DE.

Dr. Altman joined Luminex in 2007 and was appointed vice president of Luminex's Biodefense efforts in July 2010. Leveraging her background in chemical and biological defense and technology development, Dr. Altman is charged with strategy and driving growth in the biodefense market. Dr. Altman has also served as director of the Extramural Research Office and senior director of Research and Development for the Luminex Bioscience Group. She earned her BA degree in Microbiology and her MS degree in Microbiology from Miami University and earned her Ph.D. in Molecular Biology from Vanderbilt University.

The 2011 CBD S&T Conference offers attendees the opportunity to examine the best, new, dynamic developments in basic and applied research within the chemical and biological defense landscape. Attendees will interact and collaborate with other researchers concerning the medical and physical sciences related to chemical and biological defense. Attendees will also have the opportunity to meet DTRA science and technology managers and other members of the chem-bio technologies team. For more information on the CBD S&T Conference, please visit: http://cbdstconf2011.sainc.com.

About Luminex Corporation

Luminex is committed to applying its passion for innovation to advancing healthcare and research worldwide. We are transforming global healthcare and life-science research through the development, manufacturing, and marketing of proprietary instruments and assays utilizing our xMAP open-architecture, multi-analyte platform and our MultiCode real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies that deliver cost-effective and rapid results to clinicians and researchers. Our technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies.  We are meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety.  For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology please visit our website at http://www.luminexcorp.com.

Contacts

Corporate:
Harriss T. Currie
Chief Financial Officer and Vice President, Finance
Luminex Corporation
hcurrie@luminexcorp.com
512.219.8020

Investors:
Matthew Scalo
Sr. Director, Investor Relations
Luminex Corporation
mscalo@luminexcorp.com
512.219.8020

Media:
Mimi Torrington
Director, Marketing Communications
Luminex Corporation
mtorrington@luminexcorp.com
512.219.8020

Leslie Denson
Porter Novelli
Leslie.Denson@porternovelli.com
512.241.2233


'/>"/>
SOURCE Luminex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Luminex Corporation Reports Third Quarter 2011 Results
2. Luminex Corporation Receives Deloitte Technology Fast 500™ Award
3. Luminex Corporation Third Quarter Earnings Release Scheduled for November 1, 2011
4. Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna
5. Luminex Corporation to Present at Upcoming Investment Conferences In September
6. Luminex Corporation Reports Second Quarter 2011 Results
7. Luminex Corporation Receives U.S. FDA Clearance for New, Front Line Respiratory Viral Panel Test
8. Luminex Corporation Second Quarter Earnings Release Scheduled for August 8, 2011
9. Luminex Corporation Completes Acquisition of EraGen Biosciences, Inc.
10. Luminex Corporation Named Most Innovative Company of the Year and Receives Business Innovation of the Year Award for MAGPIX® System
11. Luminex Corporation Announces Agreement to Acquire EraGen Biosciences, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology:
(Date:6/26/2016)... Aliso Viejo, California (PRWEB) , ... June 26, 2016 , ... ... for Final Cut Pro X. , "Film editors can give their videos a whole ... artistically," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
Breaking Medicine News(10 mins):